secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001104659-25-101269
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharmaceuticals receives FDA Orphan Drug Designation for QRX003 in Netherton Syndrome
--------------------------------------------------------------------------------

- FDA grants Orphan Drug Designation to QRX003 for Netherton Syndrome; 7-year US exclusivity if approved.
- Designation follows EMA Orphan Drug Designation granted in May 2025.
- Two pivotal trials ongoing; enrollment completion expected Q1 2026, top-line data H2 2026, NDA submission later 2026.
- QRX003 on track to become first approved treatment for Netherton Syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925101269/0001104659-25-101269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925101269/tm2529207d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer